Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Innovo Therapeutics

Request full access

Innovo Therapeutics is committed to discovering and developing the next generation of protein degraders in areas of high unmet medical need

San Diego, United StatesFounded 2021Biotech & Life Sciences

About Innovo Therapeutics

Innovo Therapeutics, Inc. is a biopharmaceutical company established on January 14, 2020, and headquartered in San Diego, California. The company is led by founder and CEO, Dr. Weilin Xie, a seasoned scientist with deep expertise in the field of protein degradation. Dr. Xie's background includes a significant tenure at Celgene Corporation, where he was a Principal Senior Scientist, directed the fibrosis research unit, and notably co-initiated the firm's protein homeostasis drug discovery program focused on E2 and E3 ubiquitin ligases. This experience in identifying the mechanisms of blockbuster IMiD drugs provides a strong foundation for Innovo's strategic direction.

The company operates in the oncology market, concentrating on the discovery and development of protein degraders for areas with high unmet medical needs. Its business model centers on leveraging a high-throughput chemistry platform to build a differentiated pipeline and advance its programs through corporate and academic alliances. The operational strategy is a hybrid model, combining the drug discovery experience of its US team with pre-clinical resources and infrastructure in China to optimize efficiency and productivity.

Innovo's core technology is its targeted protein degradation platform, referred to as TriNovo. This platform utilizes a 'molecular glue' approach to drug development. Molecular glues are small molecules that induce a connection between a target protein and an E3 ubiquitin ligase, a component of the cell's natural protein disposal system. This induced proximity marks the disease-causing protein for destruction by the proteasome. This method allows the company to pursue targets previously considered 'undruggable' by traditional inhibitors. One of the company's lead candidates developed from this platform is INNO-220, an orally active and highly selective CK1α molecular glue degrader. INNO-220 has shown potent anti-tumor activity against B-cell lymphomas, including in models resistant to existing treatments, by promoting the degradation of casein kinase 1 alpha (CK1α). The platform has also produced INNO-235, a dual-target degrader for GSPT1 and CK1α, which shows promise for treating MYC-driven malignancies like Burkitt lymphoma.

In addition to its internal discovery engine, Innovo has secured the worldwide exclusive rights to Rosmantuzumab, a humanized monoclonal antibody targeting R-spondin 3 (RSPO3). This Phase 2 clinical program adds a later-stage asset to its pipeline. The company actively seeks pharmaceutical partnerships to advance its pipeline programs and drive value from its differentiated discovery approach.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
25.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Dec 2023 $14M $55M CICC · Ming Bioventures · Huajin Capital · Qiandao Fund ↗
ANGEL✓Equity / VC May 2022 $0 — Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Innovo Therapeutics website traffic

Latest recorded traffic for Innovo Therapeutics is 130 monthly website visits, up 8.3% over the last three months. Innovo Therapeutics's team grew 0% over the past year.

Latest monthly visits130 3-month web change+8.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Halda TherapeuticsPrecision oncology therapies targeting cancer via RIPTAC™ chimera New Haven, United States Acquired 40 $126M $3B
MatchpointDesigning a new era of precision covalent medicines informed by breakthroughs in ultradeep chemoproteomics and machine learning Boston, United States Operational
Engimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies Allschwil, Switzerland Operational
Cimeio TherapeuticsDeveloping Shielded-Cell & Drug Pairs to increase cure rates for patients with hematologic malignancies, genetic and autoimmune diseases Cambridge, United States Operational
Radionetics OncologyRadionetics Oncology is a precision oncology company focusing on the discovery and development of radiopharmaceuticals San Diego, United States Operational
Stratus TherapeuticsDeveloping off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases Natick, United States Operational
Nabla BioDeveloping AI and wet-lab technologies to enable the rational design of selective, functional drugs targeting previously undruggable sites Cambridge, United States Operational
CatenaBioCatena biosciences's mission is to create new therapies for cancer, vaccines, and to retrain the immune system to cure autoimmune disorders Berkeley, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Innovo Therapeutics in the San Diego ecosystem

Live from Dealroom

The Innovo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed5 investors entered at this stage

  • Huajin Capital
  • CICC
  • Ming Bioventures
  • Qiandao Fund
  • Hainan Longmen Fund

Other known investors2 additional known investors

  • Medical University of South Carolina
  • HMC Ventures
Employees 9 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States75%
🇰🇷 South Korea25%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Innovo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Innovo Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.